Evidence map›Paper›PMID 35499292›Full record

ArticleCancer medicine2022

Prediction of lung cancer risk in Chinese population with genetic-environment factor using extreme gradient boosting.

Yutao Li, Zixiu Zou, Zhunyi Gao, Yi Wang, Man Xiao, Chang Xu, Gengxi Jiang, Haijian Wang, Li Jin, Jiucun Wang and 3 more

Open access · goldAbstract readMulticenter Study
In one paragraph

Article in Cancer medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Lung cancer risk score for ever and never smokers in China.Cancer communications (London, England) · 2023
    Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Yutao LiSchool of Life Sciences, Fudan University, Shanghai, China.
Zixiu ZouSchool of Life Sciences, Fudan University, Shanghai, China.ORCID 0000-0001-8126-4427
Zhunyi GaoCompany 6 of Basic Medical School, Navy Military Medical University, Shanghai, China.
Yi WangSchool of Life Sciences, Fudan University, Shanghai, China.
Man XiaoDepartment of Biochemistry and Molecular Biology, Hainan Medical University, Haikou, China.
Chang XuClinical College of Xiangnan University, Chenzhou, China.
Gengxi JiangDepartment of Thoracic Surgery, the First Affiliated Hospital of Naval Medical University (Second Military Medical University), Shanghai, China.
Haijian WangSchool of Life Sciences, Fudan University, Shanghai, China.ORCID 0000-0002-4876-8022
Li JinSchool of Life Sciences, Fudan University, Shanghai, China.
Jiucun WangSchool of Life Sciences, Fudan University, Shanghai, China.
Huai Zhou WangDepartment of Laboratory Diagnosis, the First Affiliated Hospital of Naval Medical University (Second Military Medical University), Shanghai, China.
Shicheng GuoSchool of Life Sciences, Fudan University, Shanghai, China.ORCID 0000-0002-7047-9972
Junjie WuSchool of Life Sciences, Fudan University, Shanghai, China.ORCID 0000-0002-4000-7026
Fudan University · CNSecond Military Medical University · CNHainan Medical University · CNXiangnan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDetecting early-stage lung cancer is critical to reduce the lung cancer mortality rate; however, existing models based on germline variants perform poorly, and new models are needed. This study aimed to use extreme gradient boosting to develop a predictive model for the early diagnosis of lung cancer in a multicenter case-control study. MATERIALS AND

methodsA total of 974 cases and 1005 controls in Shanghai and Taizhou were recruited, and 61 single nucleotide polymorphisms (SNPs) were genotyped. Multivariate logistic regression was used to calculate the association between signal SNPs and lung cancer risk. Logistic regression (LR) and extreme gradient boosting (XGBoost) algorithms, a large-scale machine learning algorithm, were adopted to build the lung cancer risk model. In both models, 10-fold cross-validation was performed, and model predictive performance was evaluated by the area under the curve (AUC).

resultsAfter FDR adjustment, TYMS rs3819102 and BAG6 rs1077393 were significantly associated with lung cancer risk (p < 0.05). For lung cancer risk prediction, the model predicted only with epidemiology attained an AUC of 0.703 for LR and 0.744 for XGBoost. Compared with the LR model predicted only with epidemiology, further adding SNPs and applying XGBoost increased the AUC to 0.759 (p < 0.001) in the XGBoost model. BAG6 rs1077393 was the most important predictor among all SNPs in the lung cancer prediction XGBoost model, followed by TERT rs2735845 and CAMKK1 rs7214723. Further stratification in lung adenocarcinoma (ADC) showed a significantly elevated performance from 0.639 to 0.699 (p = 0.009) when applying XGBoost and adding SNPs to the model, while the best model for lung squamous cell carcinoma (SCC) prediction was the LR model predicted with epidemiology and SNPs (AUC = 0.833), compared with the XGBoost model (AUC = 0.816).

conclusionOur lung cancer risk prediction models in the Chinese population have a strong predictive ability, especially for SCC. Adding SNPs and applying the XGBoost algorithm to the epidemiologic-based logistic regression risk prediction model significantly improves model performance.

Indexed as

East Asian PeopleLung NeoplasmsCase-Control StudiesChinaHumansLungMolecular ChaperonesBAG6 protein, humanMolecular ChaperonesChinese populationextreme gradient boostinglung cancerrisk modelsingle nucleotide polymorphisms

Identifiers

PMID35499292
PMCPMC9741969
OpenAlexW4225263025

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.